KAS
AVEO

Kestra Advisory Services’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

Kestra Advisory Services’s Portfolio AVEO Stock Details AVEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-12,200
Closed -$70K – 2119
2020
Q4 		$70K Buy
+12,200
New +$69.8K ﹤0.01% 1803

Other funds holding AVEO

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
MIM
Monashee Investment Management Boston, Massachusetts $184M AUM 197.43% 1-Year Est. Return

Kestra Advisory Services's AVEO Position: Q1 2021 in Review

Kestra Advisory Services sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q1 2021, closing a stake of 12,200 shares — an estimated $70K sold.

Kestra Advisory Services first reported a position in AVEO in Q4 2020 and held it in 1 quarter. The position peaked at $70K in Q4 2020. 76 funds tracked by Wall St. Rank hold AVEO as of Q1 2021.

  • Kestra Advisory Services reported no remaining AVEO Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Kestra Advisory Services sold 12,200 AVEO Pharmaceuticals, Inc. shares in Q1 2021, an estimated $70K.
  • Kestra Advisory Services first reported a position in AVEO Pharmaceuticals, Inc. in Q4 2020 and held it in 1 quarter.
  • Kestra Advisory Services's AVEO Pharmaceuticals, Inc. position peaked at $70K in Q4 2020.
  • 76 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q1 2021.

Based on Kestra Advisory Services's 13F filing for Q1 2021, filed 10 May 2021.